<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="acr25184" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Care Res (Hoboken)</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Care Res (Hoboken)</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">ACR</journal-id><journal-title-group><journal-title>Arthritis Care &amp; Research</journal-title></journal-title-group><issn pub-type="ppub">2151-464X</issn><issn pub-type="epub">2151-4658</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10758525</article-id><article-id pub-id-type="pmcid-ver">PMC10758525.1</article-id><article-id pub-id-type="pmcaid">10758525</article-id><article-id pub-id-type="pmcaiid">11848958</article-id><article-id pub-id-type="pmid">37394710</article-id><article-id pub-id-type="doi">10.1002/acr.25184</article-id><article-id pub-id-type="publisher-id">ACR25184</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Rheumatoid Arthritis</subject><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Multimorbidity Patterns and Rheumatoid Arthritis Disease Outcomes: Findings From a Multicenter, Prospective Cohort</article-title><alt-title alt-title-type="right-running-head">MULTIMORBIDITY AND RA OUTCOMES</alt-title><alt-title alt-title-type="left-running-head">DUTT ET AL</alt-title></title-group><contrib-group><contrib id="acr25184-cr-0001" contrib-type="author"><name name-style="western"><surname>Dutt</surname><given-names initials="S">Sarah</given-names></name><xref rid="acr25184-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acr25184-cr-0002" contrib-type="author"><name name-style="western"><surname>Roul</surname><given-names initials="P">Punyasha</given-names></name><xref rid="acr25184-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acr25184-cr-0003" contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="Y">Yangyuna</given-names></name><xref rid="acr25184-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acr25184-cr-0004" contrib-type="author"><name name-style="western"><surname>Johnson</surname><given-names initials="TM">Tate M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0335-4157</contrib-id><xref rid="acr25184-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acr25184-cr-0005" contrib-type="author"><name name-style="western"><surname>Michaud</surname><given-names initials="K">Kaleb</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5350-3934</contrib-id><xref rid="acr25184-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acr25184-cr-0006" contrib-type="author"><name name-style="western"><surname>Sauer</surname><given-names initials="B">Brian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3546-3051</contrib-id><xref rid="acr25184-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acr25184-cr-0007" contrib-type="author"><name name-style="western"><surname>Cannon</surname><given-names initials="GW">Grant W.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6640-9173</contrib-id><xref rid="acr25184-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acr25184-cr-0008" contrib-type="author"><name name-style="western"><surname>Baker</surname><given-names initials="JF">Joshua F.</given-names></name><xref rid="acr25184-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acr25184-cr-0009" contrib-type="author"><name name-style="western"><surname>Curtis</surname><given-names initials="JR">Jeffrey R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8907-8976</contrib-id><xref rid="acr25184-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="acr25184-cr-0010" contrib-type="author"><name name-style="western"><surname>Mikuls</surname><given-names initials="TR">Ted R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0897-2272</contrib-id><xref rid="acr25184-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acr25184-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>England</surname><given-names initials="BR">Bryant R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9649-3588</contrib-id><xref rid="acr25184-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Bryant.england@unmc.edu</email></address></contrib></contrib-group><aff id="acr25184-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>VA Nebraska&#8208;Western Iowa Health Care System and University of Nebraska Medical Center</institution>
<city>Omaha</city>
</aff><aff id="acr25184-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>University of Nebraska Medical Center, Omaha, and FORWARD&#8211;the National Data Bank for Rheumatic Disease</institution>
<city>Wichita</city>
<named-content content-type="country-part">Kansas</named-content>
</aff><aff id="acr25184-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>VA Salt Lake City and University of Utah</institution>
<city>Salt Lake City</city>
</aff><aff id="acr25184-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Corporal Michael J. Crescenz VA Medical Center and the University of Pennsylvania</institution>
<city>Philadelphia</city>
</aff><aff id="acr25184-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>University of Alabama at Birmingham</institution>
<city>Birmingham</city>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Address correspondence via email to Bryant R. England, MD, PhD, at <email>Bryant.england@unmc.edu</email>.<break/></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2025</year></pub-date><volume>77</volume><issue seq="90">3</issue><issue-id pub-id-type="pmc-issue-id">482769</issue-id><issue-id pub-id-type="doi">10.1002/acr.v77.3</issue-id><fpage>337</fpage><lpage>348</lpage><history><date date-type="rev-recd"><day>13</day><month>6</month><year>2023</year></date><date date-type="received"><day>17</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-04 15:25:35.543"><day>04</day><month>04</month><year>2025</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">11848958</article-id><article-id pub-id-type="doi">10.1002/acr.25184</article-id><article-version>1</article-version><pub-date><day>30</day><month>10</month><year>2023</year></pub-date></event><event event-type="pmc-version" specific-use="not-live"><article-id pub-id-type="pmcaiid">10758525</article-id><article-id pub-id-type="doi">10.1002/acr.25184</article-id><article-id pub-id-type="manuscript-id">NIHMS1915474</article-id><article-version>319</article-version><pub-date><day>30</day><month>10</month><year>2023</year></pub-date><date date-type="pmc-release"><day>01</day><month>03</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2023 The Authors. <italic toggle="yes">Arthritis Care &amp; Research</italic> published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ACR-77-337.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ACR-77-337.pdf"/><abstract><sec id="acr25184-sec-0001"><title>Objective</title><p>To determine whether unique multimorbidity patterns are associated with long&#8208;term rheumatoid arthritis (RA) disease severity.</p></sec><sec id="acr25184-sec-0002"><title>Methods</title><p>We conducted a cohort study within the Veterans Affairs Rheumatoid Arthritis registry. We applied previously derived multimorbidity patterns based on the presence of diagnostic codes for relevant conditions prior to enrollment using linked administrative data. Disease activity and functional status were assessed longitudinally up to 5&#8201;years after enrollment. The association of multimorbidity patterns with disease activity and functional status were assessed using generalized estimating equations models adjusting for relevant confounders.</p></sec><sec id="acr25184-sec-0003"><title>Results</title><p>We studied 2,956 participants, of which 88.2% were male, 76.9% reported white race, and 79.3% had a smoking history. Mental health and substance abuse (&#946; 0.12 [95% confidence interval {CI} 0.00, 0.23]), cardiovascular (&#946; 0.25 [95% CI 0.12, 0.38]), and chronic pain (&#946; 0.21 [95% CI 0.11, 0.31]) multimorbidity were associated with higher Disease Activity Score in 28 joints (DAS28) scores. Mental health and substance abuse (&#946; 0.09 [0.03, 0.15]), cardiovascular (&#946; 0.11 [95% CI 0.04, 0.17]), and chronic pain multimorbidity (&#946; 0.15 [95% CI 0.10, 0.20]) were also associated with higher Multidimensional Health Assessment Questionnaire (MDHAQ) scores. The metabolic pattern of multimorbidity was not associated with DAS28 or MDHAQ. The number of multimorbidity patterns present was highly associated with DAS28 and MDHAQ (<italic toggle="no">P</italic> trend &lt;&#8201;0.001), and patients with all four multimorbidity patterns had the highest DAS28 (&#946; 0.59 [95% CI 0.36, 0.83]) and MDHAQ (&#946; 0.27 [95% CI 0.16, 0.39]) scores.</p></sec><sec id="acr25184-sec-0004"><title>Conclusion</title><p>Mental health and substance abuse, chronic pain, and cardiovascular multimorbidity patterns are associated with increased RA disease activity and poorer functional status. Identifying and addressing these multimorbidity patterns may facilitate achieving RA treatment targets.</p></sec></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases
</institution><institution-id institution-id-type="doi">10.13039/100000069</institution-id></institution-wrap></funding-source><award-id>P30 AR072583</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Institute of General Medical Sciences
</institution><institution-id institution-id-type="doi">10.13039/100000057</institution-id></institution-wrap></funding-source><award-id>U54 GM115458</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Rheumatology Research Foundation
</institution><institution-id institution-id-type="doi">10.13039/100006260</institution-id></institution-wrap></funding-source><award-id>Scientist Development Award</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>U.S. Department of Defense
</institution><institution-id institution-id-type="doi">10.13039/100000005</institution-id></institution-wrap></funding-source><award-id>PR200793</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>U.S. Department of Veterans Affairs
</institution><institution-id institution-id-type="doi">10.13039/100000738</institution-id></institution-wrap></funding-source><award-id>BX004600</award-id><award-id>CX001703</award-id><award-id>IK2 CX002203</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="12"/><word-count count="6992"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:24.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="acr25184-ntgp-0001"><fn id="acr25184-note-0001"><p>The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.</p></fn><fn id="acr25184-note-0003"><p>Dr. Johnson's work was supported by a Rheumatology Research Foundation Scientist Development award. Dr. Baker's work was supported by a VA Merit Award (grant CX&#8208;001703). Dr. Curtis's work was supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant P30&#8208;AR&#8208;072583) and the Patient Centered Outcomes Research Institute. Dr. Mikuls's work was supported by a VA Merit Award (grant BX&#8208;004600), the Department of Defense (grant PR&#8208;200793) and the NIH/National Institute of General Medical Sciences (grant U54&#8208;GM&#8208;115458). Dr. England's work was supported by a Rheumatology Research Foundation Scientist Development award, the Great Plains IDeA&#8208;CTR from the NIH/National Institute of General Medical Sciences (grant U54&#8208;GM&#8208;115458), and the VA Clinical Science Research &amp; Development (grant IK2&#8208;CX&#8208;002203).</p></fn><fn id="acr25184-note-0004"><p>Additional supplementary information cited in this article can be found online in the Supporting Information section (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1002/acr.25184" ext-link-type="uri">http://onlinelibrary.wiley.com/doi/10.1002/acr.25184</ext-link>).</p></fn><fn id="acr25184-note-0005"><p>Author disclosures are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://onlinelibrary.wiley.com/doi/10.1002/acr.25184" ext-link-type="uri">https://onlinelibrary.wiley.com/doi/10.1002/acr.25184</ext-link>.</p></fn></fn-group></notes></front><body id="acr25184-body-0001"><sec id="acr25184-sec-0005"><title>INTRODUCTION</title><p>In addition to joint manifestations, rheumatoid arthritis (RA) predisposes patients to the development of other chronic conditions such as heart disease, lung diseases, and osteoporosis, among others.<xref rid="acr25184-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The development of multiple chronic conditions, often termed multimorbidity, affects the majority of patients with RA.<xref rid="acr25184-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="acr25184-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Certain shared risk factors, such as smoking and obesity, can predispose to both RA and other chronic conditions that contribute to the burden of multimorbidity. Multimorbidity may also result from the systemic inflammatory responses accompanying RA, which are known to adversely impact several organ systems including the heart and lungs.<xref rid="acr25184-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="acr25184-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="acr25184-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="acr25184-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="acr25184-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Although multimorbidity is recognized to portend poor survival and reduced quality of life in RA,<xref rid="acr25184-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> there has been limited research investigating how multimorbidity may be associated RA severity and the RA disease course.<boxed-text position="anchor" content-type="box" id="acr25184-blkfxd-0001" orientation="portrait"><caption><title>SIGNIFICANCE &amp; INNOVATIONS</title></caption><p>
<list list-type="bullet" id="acr25184-list-0001"><list-item id="acr25184-li-0001"><p>Most people with rheumatoid arthritis (RA) are multimorbid, experiencing multiple chronic conditions.</p></list-item><list-item id="acr25184-li-0002"><p>Multimorbidity patterns are novel measures of multimorbidity occurring in people with RA, but their associations with RA&#8208;related outcomes are unknown.</p></list-item><list-item id="acr25184-li-0003"><p>We characterized cross&#8208;sectional and longitudinal associations between different multimorbidity patterns with RA disease activity and functional status in a multicenter, prospective RA cohort.</p></list-item><list-item id="acr25184-li-0004"><p>Mental health and substance abuse, chronic pain, and cardiovascular multimorbidity patterns are associated with increased RA disease activity and poorer functional status.</p></list-item></list>
</p></boxed-text>
</p><p>In some prior studies, multimorbid patients with RA were less likely to receive biologic disease&#8208;modifying antirheumatic drugs (DMARDs) or had biologic DMARD initiation postponed.<xref rid="acr25184-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="acr25184-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In contrast, in a large, real&#8208;world RA cohort study with more stringent eligibility criteria requiring multiple visits with moderate or high disease activity, there were no differences in the initiation of new DMARDs, including biologics, based on multimorbidity burden.<xref rid="acr25184-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Although there are conflicting findings regarding whether multimorbid patients with RA are treated less aggressively, perhaps depending on the health care environment, practice setting, and the predilections of the treating rheumatologist, multimorbid patients do consistently appear to be less likely to achieve the RA treatment targets of remission or low disease activity after beginning new DMARDs.<xref rid="acr25184-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="acr25184-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>A limitation of the aforementioned studies is that they typically assessed multimorbidity using a simple count of chronic conditions, which does not capture the interconnectedness of chronic conditions core to the concept of multimorbidity.<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="acr25184-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Previously, we have used independent, large, real&#8208;world data sources and machine learning approaches to derive novel multimorbidity patterns among patients with RA.<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> However, it remains unknown whether these multimorbidity patterns are associated with long&#8208;term RA&#8208;related outcomes such as RA disease activity and functional status. Therefore, the objective of this study was to determine how unique multimorbidity patterns are associated with the long&#8208;term disease course in RA. As an extension of our prior work, we hypothesized that multimorbid patients would have increased RA disease activity and poorer functional status and that these outcomes would differ across unique multimorbidity patterns. Additionally, we hypothesized that patients with a greater number of multimorbidity patterns would demonstrate more severe disease activity and functional status trajectories.</p></sec><sec id="acr25184-sec-0007"><title>PATIENTS AND METHODS</title><sec id="acr25184-sec-0009"><title>Study design and data sources</title><p>We performed a cohort study within the Veterans Affairs (VA) Rheumatoid Arthritis (VARA) registry. The VARA registry, initiated in 2003, is a multicenter, prospective cohort of US Veterans with RA diagnosed by a rheumatologist and fulfilling the 1987 American College of Rheumatology (ACR) classification criteria.<xref rid="acr25184-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> All participants provided written informed consent, and each site received Institutional Review Board (IRB) approval. This study was approved by the VA Nebraska&#8208;Western Iowa Health Care System IRB (no. 1576193).</p><p>The VARA registry has been previously described in detail.<xref rid="acr25184-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Briefly, at enrollment, patient demographics, smoking status, and RA disease history (eg, RA diagnosis date, prior treatments) are collected. ACR core measures are collected at enrollment and follow&#8208;up visits, as dictated by usual care.<xref rid="acr25184-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> These ACR core measures include 28&#8208;joint tender and swollen joint counts, patient and provider global assessments, pain, physical function, and acute&#8208;phase reactants. The registry has also previously been linked to administrative and electronic health record data in the VA Corporate Data Warehouse (CDW).<xref rid="acr25184-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="acr25184-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p></sec><sec id="acr25184-sec-0010"><title>Multimorbidity assessment</title><p>The primary exposures were unique multimorbidity patterns at the time of registry enrollment. The presence of 42 conditions used in RA multimorbidity studies<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> was assessed prior to enrollment through diagnostic codes from inpatient and outpatient encounters within the VA CDW. Patients were required to have at least two diagnostic codes for each condition from separate encounters, to reduce misclassification. All available VA data prior to the time of VARA enrollment were used (median 6.2&#8201;years). Based on the presence of these individual conditions, we applied previously developed multimorbidity patterns to the current cohort.<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> These multimorbidity patterns were derived through factor analysis of the aforementioned conditions within the VA and MarketScan Commercial Claims and Encounters Database. For this report, our primary analyses focused on multimorbidity patterns derived from the VA: mental health and substance abuse, metabolic, cardiovascular, and chronic pain. The chronic pain pattern of multimorbidity included specific chronic pain conditions and does not incorporate pain scores collected as part of RA management. We applied patterns derived in MarketScan in sensitivity analyses. Multimorbidity patterns and the individual conditions composing these patterns are listed in Supplementary Table. Consistent with prior work,<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> participants were required to have at least two conditions from the respective multimorbidity pattern for it to be considered present. Multimorbidity patterns were not mutually exclusive (ie, patients could have more than one multimorbidity pattern), and the number of multimorbidity patterns present was used as a measure of multimorbidity burden in secondary analyses.</p></sec><sec id="acr25184-sec-0011"><title>Study outcomes</title><p>The primary study outcomes were RA disease activity and physical function over up to five years of follow&#8208;up after registry enrollment. Outcome follow&#8208;up was limited to five years because of decreasing availability of the outcomes after this time and because additional multimorbidity patterns may have developed. For each year of follow&#8208;up after enrollment, we calculated the mean values for each study outcome. Disease activity was measured using the Disease Activity Score in 28 joints (DAS28).<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> DAS28 with erythrocyte sedimentation rate (ESR) was preferentially used, but if only the C&#8208;reactive protein (CRP) was available, we calculated the DAS28&#8208;CRP. Functional status was measured using the Multidimensional Health Assessment Questionnaire (MDHAQ).<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Secondary outcomes were the Clinical Disease Activity Index (CDAI)<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> and individual components of RA disease activity measures: patient global assessment (0&#8211;100), provider global assessment (0&#8211;100), tender joint count (0&#8211;28), swollen joint count (0&#8211;28), CRP, and ESR.</p></sec><sec id="acr25184-sec-0012"><title>Study covariate</title><p>We selected study covariates a priori that may confound the association between multimorbidity patterns and study outcomes. The potential cofounders accounted for included age, gender, race (self&#8208;reported), smoking status (current, former, never), education level, rheumatoid factor (RF) or anti&#8211;cyclic citrullinated peptide (CCP) antibody positivity based on standardized assays,<xref rid="acr25184-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> RA disease duration, conventional synthetic DMARD use (methotrexate, azathioprine, hydroxychloroquine, sulfasalazine, minocycline, leflunomide), biologic DMARD use (etanercept, adalimumab, infliximab, golimumab, certolizumab, abatacept, interleukin&#8208;6 inhibitors, rituximab), and prednisone use. Janus kinase inhibitors were infrequently used at enrollment (0.4%). Covariates were fixed at baseline values and collected from the VARA registry, except for medications which were obtained from linked VA CDW pharmacy dispensing data sources.</p></sec><sec id="acr25184-sec-0013"><title>Statistical analysis</title><p>Baseline characteristics of participants were assessed descriptively overall and by the presence of each multimorbidity pattern. We cross&#8208;sectionally assessed the associations of different patterns of multimorbidity with the DAS28 and MDHAQ at enrollment using ordinary least squares regression models adjusted for the aforementioned covariates. Sensitivity analyses were performed using multimorbidity patterns derived in MarketScan. In secondary analyses, we performed similar analyses of CDAI and individual disease activity components.</p><p>We longitudinally evaluated the impact of baseline multimorbidity patterns on DAS28 and MDHAQ using generalized estimation equations (GEEs) to account for the correlation of these measures among participants over time. Models were adjusted for covariates and specified an exchangeable covariance matrix. Because the multimorbidity patterns were derived to be unique patterns (ie, not highly correlated), all patterns were assessed in the same model. Interaction terms were tested between multimorbidity patterns and follow&#8208;up duration but were not significant and thus not included (all <italic toggle="yes">P</italic> &gt;&#8201;0.20; data not shown). Additional analyses adjusted for enrollment disease activity and functional status values as well as restricted the population to patients with RA with a disease duration less than two years. We evaluated the inclusion of age squared to account for nonlinear associations, but this did not affect results and was not included in final models (data not shown). We also evaluated whether the number of multimorbidity patterns (0&#8211;4), an indicator of multimorbidity burden, was associated with longitudinal DAS28 and MDHAQ scores in similar GEE models. Pattern count was used in place of specific multimorbidity patterns for these models. The association of multimorbidity patterns with CDAI and individual disease activity components was assessed through similar GEE models in secondary analyses. In these analyses, tender joint count and swollen joint count were modeled using a negative binomial distribution, whereas all other components were modeled using a Gaussian distribution. The missing&#8208;indicator method was used to handle missing covariate data. All analyses were completed using Stata version 17 (StataCorp) within the VA Informatics and Computing Infrastructure environment.</p></sec></sec><sec sec-type="results" id="acr25184-sec-0014"><title>RESULTS</title><sec id="acr25184-sec-0016"><title>Patient characteristics and multimorbidity pattern frequency</title><p>We studied 2,956 participants, of which the majority were male (88.2%), White (76.9%), and had a smoking history (79.3%). RF or anti&#8208;CCP seropositivity was present in 85.8% of participants. At enrollment, the majority (74.8%) of participants were taking conventional synthetic DMARDs, whereas 26.6% were taking biologic DMARDs and 41.0% were taking prednisone. At the five&#8208;year follow&#8208;up end of study period, 40.3% of participants had available DAS28 values, whereas 40.7% had MDHAQ values.</p><p>The metabolic multimorbidity pattern was the most frequent multimorbidity pattern (64.0%), followed by chronic pain (48.4%), mental health and substance abuse (23.2%), and cardiovascular multimorbidity (12.4%) (Table&#160;<xref rid="acr25184-tbl-0001" ref-type="table">1</xref>). Participants with cardiovascular multimorbidity were older, were more frequently male, and had a longer duration of RA. Participants with mental health and substance abuse or chronic pain multimorbidity were younger and had a higher level of education. Most (73.4%) participants had at least one multimorbidity pattern, with 24.9% having one, 26.0% having two, 19.0% having three, and 3.5% having all four multimorbidity patterns.</p><table-wrap position="float" id="acr25184-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Participant characteristics by multimorbidity patterns at registry enrollment<xref rid="acr25184-note-0006" ref-type="table-fn">*</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Characteristics</th><th rowspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Overall</th><th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multimorbidity patterns<xref rid="acr25184-note-0007" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Metabolic</th><th align="center" valign="bottom" rowspan="1" colspan="1">Chronic pain</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mental health and substance abuse</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cardiovascular</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">n (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2956</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,892 (64.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,431 (48.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">686 (23.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">366 (12.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, y</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">64.5 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">67.1 (9.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">64.9 (10.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">62.3 (9.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">70.6 (8.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male, n (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2,606 (88.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,722 (91.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,241 (86.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">572 (83.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">348 (95.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White race, n (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2,273 (76.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,450 (76.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,073 (75.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">483 (70.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">289 (79.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, mean (SD) kg/m<sup>2</sup>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">28.6 (5.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29.3 (5.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29.5 (6.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29.5 (5.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29.1 (5.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking status, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Never</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">594 (20.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">358 (19.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">266 (19.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">111 (17.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">62 (17.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Former</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,547 (54.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,083 (58.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">778 (56.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">342 (52.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">239 (66.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Current</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">726 (25.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">398 (21.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">332 (24.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">201 (30.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">57 (15.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;High school</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">303 (11.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">211 (12.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">149 (11.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">61 (10.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">55 (17.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High school</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,007 (38.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">645 (38.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">447 (35.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">181 (30.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">128 (39.5)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&gt;High school</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,300 (49.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">812 (48.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">664 (52.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">352 (59.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">141 (43.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RA duration, y</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11.4 (11.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11.8 (11.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11.0 (11.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10.2 (10.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14.7 (13.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RF or anti&#8208;CCP positive, n (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2,210 (85.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,392 (83.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,008 (82.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">480 (82.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">274 (82.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DAS28</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.8 (1.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.8 (1.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.9 (1.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.0 (1.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.1 (1.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MDHAQ</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.9 (0.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.9 (0.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.0 (0.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.1 (0.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.0 (0.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patient global (0&#8211;100)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">39.5 (25.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40.0 (25.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">43.5 (25.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">45.7 (25.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">42.4 (27.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Provider global (0&#8211;100)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">32.8 (23.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">32.6 (23.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">34.3 (23.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35.1 (23.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">36.8 (24.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tender joint count</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.7 (6.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.5 (6.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.1 (6.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.8 (7.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.9 (6.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Swollen joint count</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.7 (5.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.4 (4.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.5 (4.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.7 (5.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.9 (5.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESR</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">26.1 (22.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">27.7 (23.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">26.1 (23.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25.6 (23.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">33.7 (27.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.6 (2.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.7 (3.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.7 (3.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.5 (2.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.2 (3.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RA medications, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">csDMARDs</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2,212 (74.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,458 (77.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,084 (75.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">492 (71.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">284 (77.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Biologic DMARDs</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">786 (26.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">487 (25.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">384 (26.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">192 (28.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">82 (22.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prednisone</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1,212 (41.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">772 (40.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">611 (42.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">277 (40.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">163 (44.5)</td></tr></tbody></table><table-wrap-foot id="acr25184-ntgp-0002"><fn id="acr25184-note-0006"><label>*</label><p>BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C&#8208;reactive protein; csDMARD, conventional synthetic disease&#8208;modifying antirheumatic drug; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; MDHAQ, Multidimensional Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.</p></fn><fn id="acr25184-note-0007"><label>
<sup>a</sup>
</label><p>Patients may have more than one multimorbidity pattern. Missing data: n&#160;=&#160;98 smoking, n&#160;=&#160;347 education, n&#160;=&#160;371 seropositivity, n&#160;=&#160;249 RA duration, n&#160;=&#160;589 DAS28, n&#160;=&#160;439 MDHAQ, n&#160;=&#160;376 patient global, n&#160;=&#160;1,126 provider global, n&#160;=&#160;188 tender joint count, n&#160;=&#160;188 swollen joint count, n&#160;=&#160;330 ESR, n&#160;=&#160;533 CRP.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acr25184-sec-0017"><title>Multimorbidity patterns and <styled-content style="fixed-case" toggle="no">RA</styled-content> outcomes at enrollment</title><p>In cross&#8208;sectional analyses at the time of registry enrollment, the cardiovascular (&#946; 0.33 [95% confidence interval {CI} 0.14, 0.53]) and chronic pain (&#946; 0.17 [95% CI 0.02, 0.32]) patterns of multimorbidity were significantly associated with higher DAS28 scores (Figure&#160;<xref rid="acr25184-fig-0001" ref-type="fig">1A</xref>). DAS28 scores were numerically higher in those with mental health and substance abuse multimorbidity (&#946; 0.14 [95% CI &#8722;0.03, 0.32]), although these were not significant. For functional status, mental health and substance abuse (&#946; 0.11 [95% CI 0.04, 0.17]), cardiovascular (&#946; 0.14 [95% CI 0.06, 0.21]), and chronic pain (&#946; 0.13 [95% CI 0.07, 0.19]) multimorbidity were all significantly associated with higher MDHAQ scores (Figure&#160;<xref rid="acr25184-fig-0001" ref-type="fig">1B</xref>). Metabolic multimorbidity was not significantly associated with either DAS28 or MDHAQ scores at enrollment.</p><fig position="float" fig-type="Figure" id="acr25184-fig-0001" orientation="portrait"><label>Figure 1</label><caption><p>Cross&#8208;sectional associations of multimorbidity patterns with (A) disease activity (DAS28) and (B) functional status (MDHAQ) at the time of registry enrollment. Values are beta coefficients and 95% confidence intervals. Models adjusted for age, gender, education, smoking status, race, rheumatoid arthritis duration, rheumatoid factor or anti&#8211;cyclic citrullinated peptide seropositivity, conventional synthetic disease&#8208;modifying antirheumatic drugs (DMARDs), biologic DMARDs, and prednisone. DAS28, Disease Activity Score in 28 joints; MDHAQ, Multidimensional Health Assessment Questionnaire.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ACR-77-337-g002.jpg"/></fig></sec><sec id="acr25184-sec-0018"><title>Multimorbidity patterns and longitudinal <styled-content style="fixed-case" toggle="no">RA</styled-content> outcomes</title><p>In longitudinal analyses with up to five years of follow&#8208;up, cardiovascular (&#946; 0.25 [95% CI 0.12, 0.38]), chronic pain (&#946; 0.21 [95% CI 0.11, 0.31]), and mental health and substance abuse (&#946; 0.12 [95% CI 0.00, 0.23]) multimorbidity were significantly associated with higher DAS28 scores (Figure&#160;<xref rid="acr25184-fig-0002" ref-type="fig">2A</xref>). However, after adjusting for baseline DAS28, only the chronic pain pattern of multimorbidity remained associated with higher DAS28 scores over follow&#8208;up (&#946; 0.16 [95% CI 0.07, 0.25]); Supplementary Figure&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">1</xref>. Mental health and substance abuse (&#946; 0.09 [95% CI [0.03, 0.15]), cardiovascular (&#946; 0.11 [95% CI 0.04, 0.17]), and chronic pain (&#946; 0.15 [95% CI 0.10, 0.20]) multimorbidity patterns were also associated with higher MDHAQ during follow&#8208;up (Figure&#160;<xref rid="acr25184-fig-0002" ref-type="fig">2B</xref>). When adjusted for baseline MDHAQ, only the chronic pain (&#946; 0.09 [95% CI 0.05, 0.13]) pattern remained associated with MDHAQ scores (Supplementary Figure&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">1</xref>). Metabolic multimorbidity was not associated with longitudinal DAS28 or MDHAQ scores. In secondary analyses using the CDAI as the disease activity measure, the mental health and substance abuse (&#946; 1.25 [95% CI 0.29, 2.21]), cardiovascular (&#946; 1.38 [95% CI 0.27, 2.48]), and chronic pain (&#946; 2.02 [95% CI 1.17, 2.86]) patterns of multimorbidity remained associated with RA disease activity over follow&#8208;up (Table&#160;<xref rid="acr25184-tbl-0002" ref-type="table">2</xref>). Similar results were found when restricting the population to participants with an RA duration less than 2&#8201;years (Supplementary Table&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">2</xref>).</p><fig position="float" fig-type="Figure" id="acr25184-fig-0002" orientation="portrait"><label>Figure 2</label><caption><p>Associations of multimorbidity patterns with rheumatoid arthritis disease activity and functional status over follow&#8208;up. Longitudinal association of multimorbidity patterns with (A) disease activity (DAS28) and (B) functional status (MDHAQ) over follow&#8208;up (up to 5 years). Values are beta coefficients and 95% confidence intervals. Generalized estimating equations models adjusted for age, gender, education, smoking status, race, rheumatoid arthritis duration, rheumatoid factor or anti&#8211;cyclic citrullinated peptide seropositivity, conventional synthetic disease&#8208;modifying antirheumatic drugs (DMARDs), biologic DMARDs, and prednisone. DAS28, Disease Activity Score in 28 joints; MDHAQ, Multidimensional Health Assessment Questionnaire.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ACR-77-337-g003.jpg"/></fig><table-wrap position="float" id="acr25184-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>Associations of multimorbidity patterns with Clinical Disease Activity Index and individual disease activity components over follow&#8208;up<xref rid="acr25184-note-0008" ref-type="table-fn">*</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Multimorbidity pattern</th><th align="center" valign="bottom" rowspan="1" colspan="1">CDAI</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient global (0&#8211;100)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Provider global (0&#8211;100)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Tender joint count</th><th align="center" valign="bottom" rowspan="1" colspan="1">Swollen joint count</th><th align="center" valign="bottom" rowspan="1" colspan="1">CRP</th><th align="center" valign="bottom" rowspan="1" colspan="1">ESR</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Metabolic</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.70 (&#8722;1.51, 0.12); <italic toggle="yes">P</italic>&#160;=&#160;0.10</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.72 (&#8722;2.41, 0.97); <italic toggle="yes">P</italic>&#160;=&#160;0.40</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.53 (&#8722;2.93, &#8722;0.13); <italic toggle="yes">P</italic>&#160;=&#160;0.03<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.08 (&#8722;0.17, 0.01); <italic toggle="yes">P</italic>&#160;=&#160;0.09</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.10 (&#8722;0.19, &#8722;0.01); <italic toggle="yes">P</italic>&#160;=&#160;0.04<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.09 (&#8722;0.22, 0.04); <italic toggle="yes">P</italic>&#160;=&#160;0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (&#8722;0.87, 2.28); <italic toggle="yes">P</italic>&#160;=&#160;0.38</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic pain</td><td align="center" valign="top" rowspan="1" colspan="1">2.02 (1.17, 2.86); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.96 (4.21, 7.71); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.50 (2.04, 4.95); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.27 (0.18, 0.37); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.06 (&#8722;0.03, 0.15); <italic toggle="yes">P</italic>&#160;=&#160;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (&#8722;0.12, 0.15); <italic toggle="yes">P</italic>&#160;=&#160;0.81</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.36 (&#8722;2.00, 1.27); <italic toggle="yes">P</italic>&#160;=&#160;0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mental health and substance abuse</td><td align="center" valign="top" rowspan="1" colspan="1">1.25 (0.29, 2.21); <italic toggle="yes">P</italic>&#160;=&#160;0.01<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.58 (1.56, 5.60); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (&#8722;1.23, 2.09); <italic toggle="yes">P</italic>&#160;=&#160;0.62</td><td align="center" valign="top" rowspan="1" colspan="1">0.19 (0.08, 0.29); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (&#8722;0.08, 0.14); <italic toggle="yes">P</italic>&#160;=&#160;0.59</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (&#8722;0.13, 0.18); <italic toggle="yes">P</italic>&#160;=&#160;0.77</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.02 (&#8722;2.90, 0.85); <italic toggle="yes">P</italic>&#160;=&#160;0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiovascular</td><td align="center" valign="top" rowspan="1" colspan="1">1.38 (0.27, 2.48); <italic toggle="yes">P</italic>&#160;=&#160;0.01<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.17 (&#8722;1.11, 3.46); <italic toggle="yes">P</italic>&#160;=&#160;0.32</td><td align="center" valign="top" rowspan="1" colspan="1">3.14 (1.23, 5.05); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.01, 0.25); <italic toggle="yes">P</italic>&#160;=&#160;0.03<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.19 (0.07, 0.31); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.21 (0.03, 0.39); <italic toggle="yes">P</italic>&#160;=&#160;0.02<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">4.31 (2.19, 6.44); <italic toggle="yes">P</italic> &lt;&#8201;0.001<xref rid="acr25184-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot id="acr25184-ntgp-0003"><fn id="acr25184-note-0008"><label>*</label><p>Values are shown as &#946; (95% confidence interval) from generalized estimation equation models adjusted for age, gender, education, smoking status, race, rheumatoid arthritis duration, seropositivity, conventional synthetic disease&#8208;modifying antirheumatic drugs (DMARDs), biologic DMARDs, and prednisone. CDAI = Clinical Disease Activity Index; CRP = C&#8208;reactive protein; ESR = erythrocyte sedimentation rate.</p></fn><fn id="acr25184-note-0009"><label>
<sup>a</sup>
</label><p>Significant at <italic toggle="yes">P</italic> &lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><p>Relative to those without any multimorbidity pattern, individuals with only one pattern of multimorbidity did not have higher DAS28 or MDHAQ scores over follow&#8208;up (Figure&#160;<xref rid="acr25184-fig-0003" ref-type="fig">3A</xref>, <xref rid="acr25184-fig-0003" ref-type="fig">3B</xref>). However, participants with more than two or more multimorbidity patterns had higher DAS28 and MDHAQ scores throughout follow&#8208;up. Those with all four multimorbidity patterns had the highest DAS28 (&#946; 0.59 [95% CI 0.36, 0.83]) and MDHAQ scores (&#946; 0.27 [95% CI 0.16, 0.39]). A test of linear trend across the number of multimorbidity patterns was highly significant for DAS28 (<italic toggle="yes">P</italic> &lt;&#8201;0.001) and MDHAQ (<italic toggle="yes">P</italic> &lt;&#8201;0.001). When adjusted for baseline DAS28 or MDHAQ, similar results were obtained although effect sizes were reduced (Supplementary Figure&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">2</xref>).</p><fig position="float" fig-type="Figure" id="acr25184-fig-0003" orientation="portrait"><label>Figure 3</label><caption><p>Associations of the number of multimorbidity patterns with rheumatoid arthritis disease activity and functional status over follow&#8208;up. Longitudinal association of the number of multimorbidity patterns present with (A) disease activity (DAS28) and (B) functional status (MDHAQ) over follow&#8208;up (up to 5 years). Values are beta coefficients and 95% confidence intervals. Generalized estimating equations models adjusted for age, gender, education, smoking status, race, rheumatoid arthritis duration, rheumatoid factor or anti&#8211;cyclic citrullinated peptide seropositivity, conventional synthetic disease&#8208;modifying antirheumatic drugs (DMARDs), biologic DMARDs, and prednisone. The reference group were those with no multimorbidity patterns. DAS28, Disease Activity Score in 28 joints; MDHAQ, Multidimensional Health Assessment Questionnaire.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ACR-77-337-g001.jpg"/></fig></sec><sec id="acr25184-sec-0019"><title>Multimorbidity patterns and longitudinal disease activity components</title><p>Multimorbidity patterns were differentially associated with individual disease activity components throughout follow&#8208;up. Mental health and substance abuse (&#946; 3.58 [95% CI 1.56, 5.59]) and chronic pain (&#946; 5.96 [95% CI 4.21, 7.71) patterns of multimorbidity were associated with increased patient global assessment &#160;(Table&#160;<xref rid="acr25184-tbl-0002" ref-type="table">2</xref>). The cardiovascular (&#946; 3.14 [95% CI 1.23, 5.05]) and chronic pain (&#946; 3.50 [95% CI 2.04, 4.95]) patterns of multimorbidity were associated with increased provider global. The metabolic (&#946; &#8722;1.53 [95% CI &#8722;2.93, &#8722;0.13]) pattern of multimorbidity was associated with decreased provider global. The mental health and substance abuse (&#946; 0.19 [95% CI 0.08, 0.29]), cardiovascular (&#946; 0.13 [95% CI 0.01, 0.25]), and chronic pain (&#946; 0.27 [95% CI 0.18, 0.37]) patterns were associated with increased tender joint count over follow&#8208;up. The cardiovascular pattern of multimorbidity was the only pattern of multimorbidity associated with increased swollen joint count (&#946; 0.19 [95% CI 0.07, 0.31]), CRP (&#946; 0.21 [95% CI 0.03, 0.39]), and ESR (&#946; 4.31 [95% CI 2.19, 6.44]) over follow&#8208;up. The metabolic pattern (&#946; &#8722;0.10 [95% CI &#8722;0.19, &#8722;0.01]) of multimorbidity was associated with a lower swollen joint count.</p></sec><sec id="acr25184-sec-0020"><title>Sensitivity analyses with alternative multimorbidity patterns</title><p>To assess the robustness of findings to the definition of multimorbidity patterns, we performed sensitivity analyses applying multimorbidity patterns originally derived in MarketScan.<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The metabolic pattern of multimorbidity was most frequent (52.3%), followed by mental health and chronic pain (48.0%), vascular and neurologic (35.4%), and cardiopulmonary (22.6%) (Supplementary Table&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">3</xref>). Similar to the primary analyses, mental health and chronic pain multimorbidity and cardiopulmonary multimorbidity were associated with higher disease activity (DAS28 and CDAI) and MDHAQ scores at baseline and follow&#8208;up (Table&#160;<xref rid="acr25184-tbl-0003" ref-type="table">3</xref>, Supplementary Table&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">4</xref>), including among those with an RA duration less than 2&#8201;years (Supplementary Table&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">2</xref>). Moreover, a greater number of multimorbidity patterns were associated with higher DAS28 and MDHAQ scores. As in primary analyses, the mental health and chronic pain multimorbidity was associated with higher patient and provider global scores, whereas cardiopulmonary multimorbidity was associated more broadly with global scores, joint counts, and acute&#8208;phase reactants (Supplementary Table&#160;<xref rid="acr25184-supitem-0002" ref-type="supplementary-material">4</xref>).</p><table-wrap position="float" id="acr25184-tbl-0003" content-type="Table" orientation="portrait"><label>Table 3</label><caption><p>Association of multimorbidity patterns with disease activity and functional status at baseline and over follow&#8208;up using patterns derived in MarketScan<xref rid="acr25184-note-0010" ref-type="table-fn">*</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Multimorbidity assessment</th><th align="center" valign="bottom" rowspan="1" colspan="1">DAS28 at enrollment</th><th align="center" valign="bottom" rowspan="1" colspan="1">MDHAQ at enrollment</th><th align="center" valign="bottom" rowspan="1" colspan="1">DAS28 over follow&#8208;up</th><th align="center" valign="bottom" rowspan="1" colspan="1">DAS28 over follow&#8208;up adj. for enrollment DAS28</th><th align="center" valign="bottom" rowspan="1" colspan="1">MDHAQ over follow&#8208;up</th><th align="center" valign="bottom" rowspan="1" colspan="1">MDHAQ over follow&#8208;up adj. for enrollment MDHAQ</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Multimorbidity pattern</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Metabolic</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.06 (&#8722;0.20, 0.08); <italic toggle="yes">P</italic>&#160;=&#160;0.42</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 (&#8722;0.05, 0.06); <italic toggle="yes">P</italic>&#160;=&#160;0.93</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.01 (&#8722;0.10, 0.09); <italic toggle="yes">P</italic>&#160;=&#160;0.86</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (&#8722;0.08, 0.09); <italic toggle="yes">P</italic>&#160;=&#160;0.87</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03 (&#8722;0.07, 0.02); <italic toggle="yes">P</italic>&#160;=&#160;0.26</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.05 (&#8722;0.09, &#8722;0.01); <italic toggle="yes">P</italic>&#160;=&#160;0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mental health and chronic pain</td><td align="center" valign="top" rowspan="1" colspan="1">0.28 (0.15, 0.41); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.17 (0.12, 0.22); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.23 (0.15, 0.32); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.04, 0.20); <italic toggle="yes">P</italic>&#160;=&#160;0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.18 (0.14, 0.22); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.10 (0.06, 0.13); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Vascular and neurologic</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (&#8722;0.12, 0.20); <italic toggle="yes">P</italic>&#160;=&#160;0.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.06 (&#8722;0.00, 0.12); <italic toggle="yes">P</italic>&#160;=&#160;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.001 (&#8722;0.11, 0.11); <italic toggle="yes">P</italic>&#160;=&#160;0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (&#8722;0.07, 0.13); <italic toggle="yes">P</italic>&#160;=&#160;0.58</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.02 (&#8722;0.07, 0.03); <italic toggle="yes">P</italic>&#160;=&#160;0.40</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.03 (&#8722;0.07, 0.01); <italic toggle="yes">P</italic>&#160;=&#160;0.19</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cardiopulmonary</td><td align="center" valign="top" rowspan="1" colspan="1">0.24 (0.07, 0.42); <italic toggle="yes">P</italic>&#160;=&#160;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.06, 0.19); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.29 (0.17, 0.40); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.01, 0.23); <italic toggle="yes">P</italic>&#160;=&#160;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.06, 0.18); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.06 (0.02, 0.11); <italic toggle="yes">P</italic>&#160;=&#160;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of multimorbidity patterns</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No patterns</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Referent</td><td align="center" valign="top" rowspan="1" colspan="1">Referent</td><td align="center" valign="top" rowspan="1" colspan="1">Referent</td><td align="center" valign="top" rowspan="1" colspan="1">Referent</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1 pattern</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (0.04, 0.27); <italic toggle="yes">P</italic>&#160;=&#160;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.03, 0.23); <italic toggle="yes">P</italic>&#160;=&#160;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.07 (0.01, 0.12); <italic toggle="yes">P</italic>&#160;=&#160;0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (&#8722;0.02, 0.07); <italic toggle="yes">P</italic>&#160;=&#160;0.31</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2 patterns</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="top" rowspan="1" colspan="1">0.22 (0.10, 0.33); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.03, 0.25); <italic toggle="yes">P</italic>&#160;=&#160;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.06, 0.18); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.05 (&#8722;0.00, 0.09); <italic toggle="yes">P</italic>&#160;=&#160;0.06</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3 patterns</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.01, 0.27); <italic toggle="yes">P</italic>&#160;=&#160;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.07 (&#8722;0.06, 0.19); <italic toggle="yes">P</italic>&#160;=&#160;0.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.05, 0.18); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (&#8722;0.04, 0.07); <italic toggle="yes">P</italic>&#160;=&#160;0.52</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">4 patterns</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (0.56, 0.87); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.28, 0.57); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.30 (0.22, 0.38); <italic toggle="yes">P</italic> &lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.09 (0.03, 0.16); <italic toggle="yes">P</italic>&#160;=&#160;0.01</td></tr></tbody></table><table-wrap-foot id="acr25184-ntgp-0004"><fn id="acr25184-note-0010"><label>*</label><p>Values shown as &#946; (95% confidence interval); <italic toggle="yes">P</italic> value. Models adjusted for age, gender, education, smoking status, race, rheumatoid arthritis duration, seropositivity, conventional synthetic disease&#8208;modifying antirheumatic drugs (DMARDs), biologic DMARDs, and prednisone. DAS28, 28&#8208;Joint Disease Activity Score; MDHAQ, Multidimensional Health Assessment Questionnaire.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="acr25184-sec-0021"><title>DISCUSSION</title><p>Multimorbidity is a growing public health problem that preferentially affects people with RA and contributes to several poor long&#8208;term health outcomes.<xref rid="acr25184-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Although multimorbidity has primarily been studied using chronic disease counts or comorbidity indices,<xref rid="acr25184-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="acr25184-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="acr25184-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> novel tools have been developed in the general population and RA to better assess multimorbidity.<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="acr25184-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="acr25184-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In this study, we applied machine learning&#8211;derived multimorbidity patterns to a large prospective RA cohort to evaluate the association of these distinct multimorbidity patterns with RA disease activity and functional status over time. Patients with a greater burden of multimorbidity based on possessing several distinct multimorbidity patterns (ie, multidimensional multimorbidity) had a more severe disease course over follow&#8208;up. The multimorbidity patterns of mental health and substance abuse, cardiovascular, and chronic pain were all associated with higher longitudinal disease activity and worse functional status scores, but their effect on the individual components of disease activity scores varied by multimorbidity pattern. These findings illustrate the important differential associations of multimorbidity with RA&#8208;related outcomes and the potential for gains that could be realized by identifying and treating (or better, preventing) multimorbidity as part of holistic RA management.</p><p>We found that patients with the cardiovascular, mental health and substance abuse, and chronic pain patterns of multimorbidity were associated with worse disease activity and functional status over follow&#8208;up. Demonstrating the robustness of these findings, similar results were obtained when using multimorbidity patterns that were derived in an alternative data set. Together, these findings clearly illustrate that patients with RA with multimorbidity can have a more difficult disease course. Although we are unaware of prior studies that have assessed multimorbidity patterns and RA outcomes, these findings build on prior reports of individual comorbidities. Chronic mental health conditions such as depression, anxiety, and posttraumatic stress disorder are associated with increased RA disease activity and proinflammatory cytokine expression.<xref rid="acr25184-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="acr25184-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="acr25184-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="acr25184-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Links between RA disease severity and cardiovascular disease are also well established,<xref rid="acr25184-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="acr25184-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> as are those with chronic pain disorders such as fibromyalgia.<xref rid="acr25184-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> In contrast, the metabolic pattern of multimorbidity was not associated with worse disease activity or functional status in our study. This contrasts with prior studies that have found metabolic syndrome<xref rid="acr25184-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="acr25184-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> and obesity<xref rid="acr25184-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> to be associated with RA disease severity. We speculate that prior studies&#8217; focus on the specific metabolic conditions of obesity and metabolic syndrome rather than our broader evaluation of metabolic multimorbidity, which includes several other related conditions (eg, vision changes, sleep disorders), as well as less ability to adjust for relevant covariates in prior studies could explain these differences. Additionally, we may not have been able to detect a meaningful impact of metabolic multimorbidity on RA outcomes because the majority of participants in our study (64%) had metabolic multimorbidity.</p><p>With several multimorbidity patterns being associated with longitudinal disease activity, we further evaluated whether they differentially affected the individual components of RA disease activity measures. The chronic pain and mental health and substance abuse patterns were associated with higher global scores and tender joint counts. In contrast, the cardiovascular pattern of multimorbidity was associated with higher provider global scores, tender and swollen joint counts, and acute&#8208;phase reactants. These findings extend insights gained from prior studies of individual comorbidities. The patient&#8208;derived components of composite disease activity measures are higher in patients with RA with fibromyalgia, but swollen joint counts and inflammatory measures do not seem to be altered.<xref rid="acr25184-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Similar results are seen in patients with RA with posttraumatic stress disorder.<xref rid="acr25184-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> CVD in RA appears to be more closely related to inflammatory burden, both in the joints (eg, joint counts) and systemically (eg, acute&#8208;phase reactants).<xref rid="acr25184-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="acr25184-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Thus, the unique relationships between these individual conditions and disease activity components is captured by multimorbidity patterns and may aid in disease activity assessment.</p><p>Most assessments of multimorbidity or comorbidity in RA have used comorbidity counts or indices. Although these intend to measure multimorbidity or comorbidity burden, they may be heavily influenced by a group of highly related conditions (eg, several cardiovascular diseases or cardiovascular disease risk factors). We have recently proposed an alternative method of multimorbidity assessment, the number of distinct multimorbidity patterns present.<xref rid="acr25184-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> In this study, we applied this multimorbidity burden measure and assessed its relationship with RA disease outcomes. Participants with a greater number of multimorbidity patterns were more likely to have higher disease activity and poorer functional status throughout follow&#8208;up. Furthermore, the associations with RA disease outcomes persisted even when adjusting for disease activity or functional status values at enrollment. These findings provide construct validity for the novel multimorbidity measure and provide the first evidence that independent multimorbidity patterns are prognostic of the RA disease course. This is important for clinicians assessing real&#8208;world patients with RA who are typically multimorbid<xref rid="acr25184-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="acr25184-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> and also for risk&#8208;adjustment purposes, as achievement of disease activity and functional status thresholds is considered a measure of quality of care.</p><p>Although we found persistent associations between multimorbidity and RA disease outcomes, there are several reasons these findings do not imply causation. As with all observational studies, unmeasured and residual confounding are potentially problematic. Additionally, interaction terms between multimorbidity patterns and time were not significant. This indicates that the trajectory of disease outcomes over time did not significantly differ by multimorbidity pattern. In fact, most differences in disease activity and functional status throughout follow&#8208;up were present at enrollment, which accounted for our decision to not adjust for baseline disease activity and functional status in our primary analysis. Once we adjusted for enrollment values, our findings were significantly attenuated, with only the chronic pain and highest number of multimorbidity pattern groups continuing to have poorer RA disease outcome measures throughout follow&#8208;up. However, this should not diminish the findings because we assessed prevalent multimorbidity at enrollment. Thus, an influence of multimorbidity on these RA outcome measures may already have occurred. Additional studies with complex time&#8208;varying assessments of multimorbidity and RA outcomes are needed to address this issue, to understand whether preventing multimorbidity may be possible, and to determine whether such interventions can influence their impact on subsequent RA outcomes.</p><p>There are limitations to this study. This study focused on the primary multimorbidity patterns found in patients with RA but was unable to assess all potential patterns of chronic diseases a patient with RA may have. Assessment of conditions in these patterns relied on linked administrative claims data, which may result in misclassification and prevents evaluation of the severity of conditions. This study did not evaluate whether conditions comprising the multimorbidity patterns were being appropriately managed. The study population was predominantly male, consistent with the characteristics of enrollees in the VA, but this may affect the generalizability. Additionally, this study did not investigate how different combinations of multimorbidity patterns may have a greater or lesser impact on RA functional status and disease activity than other combinations. Estimates for associations between multimorbidity patterns and RA disease activity did not exceed minimum important differences, suggesting that at a population level, the magnitude of association may be modest. RA disease severity and multimorbidity are likely intertwined in a bidirectional relationship. Therefore, in this prevalent RA cohort, it is possible that preceding RA disease activity and functional status were the drivers of multimorbidity at enrollment. Because the availability of DAS28 and MDHAQ measures decreased over follow&#8208;up, our results may more closely reflect the associations between multimorbidity patterns and these measures over the earlier follow&#8208;up period. Finally, changes in RA treatments throughout follow&#8208;up were not assessed as mediators of observed associations, which will require future study.</p><p>In conclusion, patients with RA suffering from a greater burden of multimorbidity and the specific patterns of mental health and substance abuse, cardiovascular, and chronic pain multimorbidity were found to have an RA disease course with higher disease activity and poorer functional status. Targeting the identification and management of multimorbidity in patients with RA could facilitate achieving RA treatment targets and optimize long&#8208;term patient outcomes.</p></sec><sec id="acr25184-sec-0022"><title>AUTHOR CONTRIBUTIONS</title><p>All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. England had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><sec id="acr25184-sec-0023"><title>Study conception and design</title><p>Dutt, England.</p></sec><sec id="acr25184-sec-0024"><title>Acquisition of data</title><p>Roul, Yang, Sauer, Cannon, Baker, Mikuls, England.</p></sec><sec id="acr25184-sec-0025"><title>Analysis and interpretation of data</title><p>Dutt, Roul, Yang, Johnson, Michaud, Sauer, Cannon, Baker, Curtis, Mikuls, England.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="acr25184-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Disclosure Form
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACR-77-337-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="acr25184-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Appendix S1:</bold> Supplementary Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACR-77-337-s002.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list id="acr25184-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="acr25184-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="acr25184-cit-0001"><string-name name-style="western"><surname>Barnett</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mercer</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Norbury</surname><given-names>M</given-names></string-name>, et al. <article-title>Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross&#8208;sectional study</article-title>. <source>Lancet</source><year>2012</year>;<volume>380</volume>:<fpage>37</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">22579043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)60240-2</pub-id></mixed-citation></ref><ref id="acr25184-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="acr25184-cit-0002"><string-name name-style="western"><surname>England</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Roul</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015</article-title>. <source>Ann Rheum Dis</source><year>2020</year>;<volume>80</volume>:<fpage>286</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">33032999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2020-218282</pub-id><pub-id pub-id-type="pmcid">PMC10658760</pub-id></mixed-citation></ref><ref id="acr25184-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="acr25184-cit-0003"><string-name name-style="western"><surname>Crowson</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Gunderson</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Dykhoff</surname><given-names>HJ</given-names></string-name>, et al. <article-title>Comprehensive assessment of multimorbidity burden in a population&#8208;based cohort of patients with rheumatoid arthritis</article-title>. <source>RMD Open</source><year>2022</year>;<volume>8</volume>:<elocation-id>e002022</elocation-id>.<pub-id pub-id-type="pmid">35042730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/rmdopen-2021-002022</pub-id><pub-id pub-id-type="pmcid">PMC8768925</pub-id></mixed-citation></ref><ref id="acr25184-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="acr25184-cit-0004"><string-name name-style="western"><surname>Radner</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Frits</surname><given-names>M</given-names></string-name>, et al. <article-title>The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease&#8208;modifying anti&#8208;rheumatic drugs</article-title>. <source>Rheumatology (Oxford)</source><year>2015</year>;<volume>54</volume>:<fpage>2076</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">26163688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/kev239</pub-id></mixed-citation></ref><ref id="acr25184-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="acr25184-cit-0005"><string-name name-style="western"><surname>Spagnolo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Sverzellati</surname><given-names>N</given-names></string-name>, et al. <article-title>The lung in rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source><year>2018</year>;<volume>70</volume>:<fpage>1544</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.40574</pub-id><pub-id pub-id-type="pmid">29806092</pub-id></mixed-citation></ref><ref id="acr25184-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="acr25184-cit-0006"><string-name name-style="western"><surname>England</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Hershberger</surname><given-names>D</given-names></string-name>. <article-title>Management issues in rheumatoid arthritis&#8208;associated interstitial lung disease [review]</article-title>. <source>Curr Opin Rheumatol</source><year>2020</year>;<volume>32</volume>:<fpage>255</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">32141954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BOR.0000000000000703</pub-id><pub-id pub-id-type="pmcid">PMC7331796</pub-id></mixed-citation></ref><ref id="acr25184-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="acr25184-cit-0007"><string-name name-style="western"><surname>England</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Thiele</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>DR</given-names></string-name>, et al. <article-title>Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications [review]</article-title>. <source>BMJ</source><year>2018</year>;<volume>361</volume>:<elocation-id>k1036</elocation-id>.<pub-id pub-id-type="pmid">29685876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k1036</pub-id><pub-id pub-id-type="pmcid">PMC6889899</pub-id></mixed-citation></ref><ref id="acr25184-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="acr25184-cit-0008"><string-name name-style="western"><surname>Canning</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Siebert</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jani</surname><given-names>BD</given-names></string-name>, et al. <article-title>Examining the relationship between rheumatoid arthritis, multimorbidity and adverse health&#8208;related outcomes: a systematic review</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2022</year>;<volume>74</volume>:<fpage>1500</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">33650196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.24587</pub-id><pub-id pub-id-type="pmcid">PMC11475560</pub-id></mixed-citation></ref><ref id="acr25184-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="acr25184-cit-0009"><string-name name-style="western"><surname>Radner</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hmamouchi</surname><given-names>I</given-names></string-name>, et al. <article-title>Treatment patterns of multimorbid patients with rheumatoid arthritis: results from an international cross&#8208;sectional study</article-title>. <source>J Rheumatol</source><year>2015</year>;<volume>42</volume>:<fpage>1099</fpage>&#8211;<lpage>104</lpage>.<pub-id pub-id-type="pmid">26034147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.141534</pub-id></mixed-citation></ref><ref id="acr25184-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="acr25184-cit-0010"><string-name name-style="western"><surname>Armagan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sari</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Erden</surname><given-names>A</given-names></string-name>, et al. <article-title>Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: single center real life results</article-title>. <source>Medicine (Baltimore)</source><year>2018</year>;<volume>97</volume>:<elocation-id>e9930</elocation-id>.<pub-id pub-id-type="pmid">29595700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000009930</pub-id><pub-id pub-id-type="pmcid">PMC5895384</pub-id></mixed-citation></ref><ref id="acr25184-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="acr25184-cit-0011"><string-name name-style="western"><surname>England</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, et al. <article-title>Influence of multimorbidity on new treatment initiation and achieving target disease activity thresholds in active rheumatoid arthritis: a cohort study using the Rheumatology Informatics System for Effectiveness (RISE) Registry</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2021</year>;<volume>75</volume>:<fpage>231</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.24762</pub-id><pub-id pub-id-type="pmcid">PMC8807743</pub-id><pub-id pub-id-type="pmid">34338449</pub-id></mixed-citation></ref><ref id="acr25184-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="acr25184-cit-0012"><string-name name-style="western"><surname>England</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Roul</surname><given-names>P</given-names></string-name>, et al. <article-title>Identification of multimorbidity patterns in rheumatoid arthritis through machine learning</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2023</year>;<volume>75</volume>:<fpage>220</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">35588095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.24956</pub-id><pub-id pub-id-type="pmcid">PMC10009900</pub-id></mixed-citation></ref><ref id="acr25184-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="acr25184-cit-0013"><string-name name-style="western"><surname>Crowson</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Gunderson</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JM</given-names><suffix>III</suffix></string-name>, et al. <article-title>Using unsupervised machine learning methods to cluster comorbidities in a population&#8208;based cohort of patients with rheumatoid arthritis</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2023</year>;<volume>75</volume>:<fpage>210</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">35724274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.24973</pub-id><pub-id pub-id-type="pmcid">PMC9763549</pub-id></mixed-citation></ref><ref id="acr25184-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="acr25184-cit-0014"><string-name name-style="western"><surname>Arnett</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Edworthy</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bloch</surname><given-names>DA</given-names></string-name>, et al. <article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source><year>1988</year>;<volume>31</volume>:<fpage>315</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">3358796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.1780310302</pub-id></mixed-citation></ref><ref id="acr25184-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="acr25184-cit-0015"><string-name name-style="western"><surname>Mikuls</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Reimold</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kerr</surname><given-names>GS</given-names></string-name>, et al. <article-title>Insights and implications of the VA rheumatoid arthritis registry [review]</article-title>. <source>Fed Pract</source><year>2015</year>;<volume>32</volume>:<fpage>24</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmcid">PMC6363303</pub-id><pub-id pub-id-type="pmid">30766061</pub-id></mixed-citation></ref><ref id="acr25184-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="acr25184-cit-0016"><string-name name-style="western"><surname>Felson</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Boers</surname><given-names>M</given-names></string-name>, et al. <article-title>The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials</article-title>. <source>Arthritis Rheum</source><year>1993</year>;<volume>36</volume>:<fpage>729</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">8507213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.1780360601</pub-id></mixed-citation></ref><ref id="acr25184-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="acr25184-cit-0017"><string-name name-style="western"><surname>George</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Sauer</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>CC</given-names></string-name>, et al. <article-title>Biologic and glucocorticoid use after methotrexate initiation in patients with rheumatoid arthritis</article-title>. <source>J Rheumatol</source><year>2018</year>;<volume>46</volume>:<fpage>343</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">30275262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.180178</pub-id><pub-id pub-id-type="pmcid">PMC6443489</pub-id></mixed-citation></ref><ref id="acr25184-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="acr25184-cit-0018"><string-name name-style="western"><surname>England</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Sayles</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Michaud</surname><given-names>K</given-names></string-name>, et al. <article-title>Chronic lung disease in U.S. veterans with rheumatoid arthritis and the impact on survival</article-title>. <source>Clin Rheumatol</source><year>2018</year>;<volume>37</volume>:<fpage>2907</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">30280369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10067-018-4314-9</pub-id><pub-id pub-id-type="pmcid">PMC6442481</pub-id></mixed-citation></ref><ref id="acr25184-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="acr25184-cit-0019"><string-name name-style="western"><surname>Miriovsky</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Michaud</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Thiele</surname><given-names>GM</given-names></string-name>, et al. <article-title>Anti&#8208;CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source><year>2010</year>;<volume>69</volume>:<fpage>1292</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20439294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard.2009.122739</pub-id><pub-id pub-id-type="pmcid">PMC3122886</pub-id></mixed-citation></ref><ref id="acr25184-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="acr25184-cit-0020"><string-name name-style="western"><surname>Prados&#8208;Torres</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Calderon&#8208;Larranaga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hancco&#8208;Saavedra</surname><given-names>J</given-names></string-name>, et al. <article-title>Multimorbidity patterns: a systematic review [review]</article-title>. <source>J Clin Epidemiol</source><year>2014</year>;<volume>67</volume>:<fpage>254</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">24472295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2013.09.021</pub-id></mixed-citation></ref><ref id="acr25184-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="acr25184-cit-0021"><string-name name-style="western"><surname>Matcham</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Irving</surname><given-names>K</given-names></string-name>, et al. <article-title>Are depression and anxiety associated with disease activity in rheumatoid arthritis?</article-title><source>A prospective study. BMC Musculoskelet Disord</source><year>2016</year>;<volume>17</volume>:<fpage>155</fpage>.<pub-id pub-id-type="pmid">27068100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12891-016-1011-1</pub-id><pub-id pub-id-type="pmcid">PMC4827220</pub-id></mixed-citation></ref><ref id="acr25184-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="acr25184-cit-0022"><string-name name-style="western"><surname>Michelsen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kristianslund</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Sexton</surname><given-names>J</given-names></string-name>, et al. <article-title>Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR&#8208;DMARD study</article-title>. <source>Ann Rheum Dis</source><year>2017</year>;<volume>76</volume>:<fpage>1906</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">28733473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2017-211284</pub-id></mixed-citation></ref><ref id="acr25184-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="acr25184-cit-0023"><string-name name-style="western"><surname>Mikuls</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Padala</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Sayles</surname><given-names>HR</given-names></string-name>, et al. <article-title>Prospective study of posttraumatic stress disorder and disease activity outcomes in US veterans with rheumatoid arthritis</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2013</year>;<volume>65</volume>:<fpage>227</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">22740431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.21778</pub-id></mixed-citation></ref><ref id="acr25184-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="acr25184-cit-0024"><string-name name-style="western"><surname>Maloley</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>England</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Sayles</surname><given-names>H</given-names></string-name>, et al. <article-title>Post&#8208;traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis</article-title>. <source>Semin Arthritis Rheum</source><year>2019</year>;<volume>49</volume>:<fpage>229</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">30777365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semarthrit.2019.02.002</pub-id><pub-id pub-id-type="pmcid">PMC6687567</pub-id></mixed-citation></ref><ref id="acr25184-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="acr25184-cit-0025"><string-name name-style="western"><surname>Crepaldi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Scire</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Carrara</surname><given-names>G</given-names></string-name>, et al. <article-title>Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis</article-title>. <source>PLoS One</source><year>2016</year>;<volume>11</volume>:<elocation-id>e0146991</elocation-id>.<pub-id pub-id-type="pmid">26757209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0146991</pub-id><pub-id pub-id-type="pmcid">PMC4710534</pub-id></mixed-citation></ref><ref id="acr25184-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="acr25184-cit-0026"><string-name name-style="western"><surname>Duffield</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>, et al. <article-title>Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta&#8208;analysis [review]</article-title>. <source>Rheumatology (Oxford)</source><year>2018</year>;<volume>57</volume>:<fpage>1453</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">29788461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/key112</pub-id><pub-id pub-id-type="pmcid">PMC6055651</pub-id></mixed-citation></ref><ref id="acr25184-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="acr25184-cit-0027"><string-name name-style="western"><surname>Da Cunha</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Brenol</surname><given-names>CV</given-names></string-name>, <string-name name-style="western"><surname>Brenol</surname><given-names>JC</given-names></string-name>, et al. <article-title>Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity</article-title>. <source>Scand J Rheumatol</source><year>2012</year>;<volume>41</volume>:<fpage>186</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">22416768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/03009742.2011.626443</pub-id></mixed-citation></ref><ref id="acr25184-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="acr25184-cit-0028"><string-name name-style="western"><surname>Karvounaris</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Sidiropoulos</surname><given-names>PI</given-names></string-name>, <string-name name-style="western"><surname>Papadakis</surname><given-names>JA</given-names></string-name>, et al. <article-title>Metabolic syndrome is common among middle&#8208;to&#8208;older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross&#8208;sectional, controlled, study</article-title>. <source>Ann Rheum Dis</source><year>2007</year>;<volume>66</volume>:<fpage>28</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">16793841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard.2006.053488</pub-id><pub-id pub-id-type="pmcid">PMC1798406</pub-id></mixed-citation></ref><ref id="acr25184-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="acr25184-cit-0029"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hazlewood</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Kaplan</surname><given-names>GG</given-names></string-name>, et al. <article-title>Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta&#8208;analysis [review]</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2016</year>; <volume>69</volume>:<fpage>157</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">27159376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.22932</pub-id></mixed-citation></ref><ref id="acr25184-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="acr25184-cit-0030"><string-name name-style="western"><surname>Lee</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Hackett</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Frits</surname><given-names>M</given-names></string-name>, et al. <article-title>Multibiomarker disease activity score and C&#8208;reactive protein in a cross&#8208;sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia</article-title>. <source>Rheumatology (Oxford)</source><year>2016</year>;<volume>55</volume>:<fpage>640</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26608972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/kev388</pub-id><pub-id pub-id-type="pmcid">PMC4795537</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>